Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 12/20 | 0.43 |
| ▸ | IGF1R | P08069 | 6/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.40 |
| ▸ | MST1R | Q04912 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12003838 | 0.91 | KDR (0.47) | KDRPDGFRAMETIGF1RAXL | |
| SCHEMBL12003860 | 0.87 | MET (0.52) | KDRPDGFRAMETIGF1RAXL | |
| SCHEMBL12004062 | 0.85 | MET (0.51) | KDRMETAXLFLT4TEK | |
| SCHEMBL3233739 | 0.84 | KDR (0.49) | KDRPDGFRAMETIGF1RHSPB1 | |
| SCHEMBL12004095 | 0.80 | HSPB1 (0.46) | KDRPDGFRAMETAXLHSPB1 | |
| SCHEMBL12003799 | 0.79 | CTSV (0.48) | METHSPB1MAPT | |
| SCHEMBL21201172 | 0.79 | MET (0.49) | KDRPDGFRAMETAXLHSPB1 | |
| SCHEMBL30616303 | 0.79 | MET (0.49) | KDRPDGFRAMETAXLHSPB1 | |
| SCHEMBL27886827 | 0.78 | HSPB1 (0.47) | KDRPDGFRAMETHSPB1ALDH1A1 | |
| SCHEMBL9824190 | 0.77 | S1PR4 (0.47) | HSPB1PPARDALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598400-B2 | Substituted quinoline compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2680886-B1 | SUBSTITUTED QUINOLINE COMPOUNDS | CALITOR SCIENCES LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20150342945-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-12-03 | — | — | US | disclosed |
| US-9133162-B2 | Substituted quinoline compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-09-15 | — | — | US | disclosed |
| EP-2680886-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012118632-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | XI NING (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20120219522-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | XI, Dr. Ning (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342945-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | MKI67, MCL1, NRAS | KDR 577/4885PDGFRA 679/4885MET 997/4885 |
| US-20120219522-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | MKI67, MCL1, NRAS | KDR 577/4885PDGFRA 679/4885MET 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.